KARDIA-3
-
Genentech, Alnylam Launch Global Phase III Trial of Zilebesiran for Uncontrolled Hypertension
Genentech and Alnylam plan to initiate a Phase III trial for zilebesiran, an RNAi therapeutic for hypertension, informed by positive Phase II KARDIA program data. The KARDIA-3 study showed zilebesiran achieved clinically meaningful reductions in systolic blood pressure at month three, sustained through month six, with encouraging safety. The ZENITH Phase III trial will enroll approximately 11,000 patients with uncontrolled hypertension to evaluate zilebesiran’s impact on cardiovascular outcomes. Zilebesiran offers twice-yearly dosing and targets a key regulator of blood pressure.
